MARKET

BOLD

BOLD

Audentes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.97
-0.01
-0.02%
Delisted 09:30 01/17 EST
OPEN
59.98
PREV CLOSE
59.98
HIGH
59.99
LOW
59.97
VOLUME
2.15M
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
22.00
MARKET CAP
2.75B
P/E (TTM)
-15.0584
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BOLD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BOLD News

  • 2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD)
  • Insider Monkey.5d ago
  • AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
  • Zacks.01/10 23:08
  • Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
  • Zacks.01/09 14:48
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About BOLD

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
More

Webull offers Audentes Therapeutics Inc (BOLD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.